February 2022 Test Bulletin

February 10, 2022

In this bulletin, Alverno Laboratories provided several updates for healthcare providers. Firstly, they postponed the implementation of the Extensive Urine Drug Confirmation Panel to February 23, 2022, discontinuing the Pain Management Panel and introducing a more comprehensive replacement. Secondly, effective April 5, 2022, they updated the calculation of estimated glomerular filtration rate (eGFR) to the new CKD-EPI 2021 equation, removing the race coefficient to improve accuracy and avoid potential biases. Additionally, they emphasized the availability of weekly data on respiratory pathogen positivity trends on their website, collected from multi-target assays. These updates aim to enhance diagnostic precision, streamline testing processes, and provide valuable insights for patient care.